Savillex Completes Acquisition of Entegris Life Sciences Fluid Management Business to Expand Single-Use Bioprocessing Portfolio
Savillex, LLC, a leading provider of high-purity fluid handling solutions for life sciences and laboratory applications worldwide, has completed its acquisition of Entegris, Inc.’s Life Sciences Fluid Management business. The transaction expands Savillex’s portfolio of products for biopharmaceutical and pharmaceutical manufacturing, strengthening its capabilities in single-use technologies and high-purity fluid management solutions used throughout drug development and production.
The acquired business includes a range of bioprocessing and pharmaceutical manufacturing products, including Aramus™ and polyethylene (PE) bags, single-use assemblies, and fluid management components. These products support applications spanning early-stage discovery, clinical development, and commercial-scale manufacturing.
Through the acquisition, Savillex is expanding its offering of high-performance single-use solutions while welcoming an experienced team with established expertise in fluid management technologies. The combined portfolio is expected to provide pharmaceutical and biopharmaceutical customers with access to a broader range of products, additional technical expertise, and expanded capabilities to address increasingly complex manufacturing requirements.
The transaction represents another step in Savillex’s strategy to strengthen its position in the life sciences market by investing in technologies, product development, and customer partnerships. By integrating complementary product portfolios and technical capabilities, the company aims to support customers across multiple stages of the drug development lifecycle and help simplify critical bioprocessing workflows.
Financial terms of the transaction were not disclosed.
Acquisition Expands Savillex’s Life Sciences Portfolio
The acquisition adds established fluid management technologies to Savillex’s existing portfolio of high-purity solutions for laboratory, pharmaceutical, and biopharmaceutical applications. The acquired product range includes Aramus™ and PE bags, single-use assemblies, and related components designed for use in bioprocessing and pharmaceutical manufacturing environments.
Single-use technologies have become an important part of modern biopharmaceutical production. These systems are used in applications where disposable fluid-contact products and assemblies can support the transfer, handling, and processing of materials throughout manufacturing operations.
By incorporating the acquired products into its broader portfolio, Savillex aims to offer customers a more comprehensive range of fluid management solutions. The expanded offering is intended to support different operational requirements, from research and early development through clinical manufacturing and commercial production.
For pharmaceutical manufacturers, product compatibility, material quality, process consistency, and reliable fluid handling are important considerations when selecting components for critical applications. As manufacturing processes become more sophisticated, suppliers are increasingly expected to provide products and technical support that can accommodate a wide range of production environments.
The integration of the Life Sciences Fluid Management business is expected to enhance Savillex’s ability to address these requirements. The company will be able to draw on the acquired product portfolio and the technical experience of the incoming team to broaden the solutions available to customers.
The addition of the Aramus™ product line is particularly relevant to Savillex’s existing containment and bioprocessing offerings. According to the company, the acquired business complements its current capabilities and creates opportunities to provide a wider selection of high-value fluid management products.
Rather than focusing solely on individual components, the expanded portfolio is intended to help customers access complementary solutions that can be used across different stages of their manufacturing processes.
The acquired business serves applications across discovery, clinical development, and commercial manufacturing. This breadth is important because pharmaceutical products move through several stages before reaching patients, with each stage involving different requirements for process development, material handling, quality, and production scale.
Supporting Biopharmaceutical Manufacturing Across the Drug Development Lifecycle
During early research and discovery, scientists and development teams work to identify promising therapeutic candidates and establish the processes needed to produce and evaluate them. Fluid handling products can support the movement and management of materials during laboratory work and preliminary process development.
As programs advance into clinical development, manufacturing processes must support the production of materials for clinical studies. Requirements may become more demanding as production workflows are refined and manufacturers work to establish reproducible processes suitable for continued development.
Commercial manufacturing introduces additional operational considerations, including the need to support routine production, maintain quality standards, and manage increasingly complex manufacturing activities. Fluid management components and single-use assemblies play a role in these environments by supporting the handling of materials used throughout production workflows.
By expanding its portfolio across these applications, Savillex aims to support customers as their programs progress from early development to larger-scale manufacturing.
The combination of its existing products with the acquired Life Sciences Fluid Management technologies could also provide customers with access to a broader supplier offering. This may be relevant for organizations seeking to streamline supplier relationships or identify compatible products for interconnected manufacturing operations.
However, the specific benefits will depend on how the acquired products are integrated into Savillex’s commercial and technical operations and how customers incorporate the expanded portfolio into their existing processes.
Single-Use Solutions Address Evolving Manufacturing Needs
Single-use technologies are an established component of many biopharmaceutical manufacturing workflows. Bags, assemblies, and related fluid handling components can be used to manage materials at different stages of production, depending on the process design and the requirements of the application.
The use of disposable components can reduce the need to clean and prepare certain reusable product-contact equipment between operations. Depending on the system and process, this approach may help manufacturers manage operational complexity and reduce some of the activities associated with equipment changeovers.
Nevertheless, selecting single-use products requires careful consideration of factors such as material compatibility, product quality, process conditions, and the requirements of the specific manufacturing application. Manufacturers must evaluate whether individual components are suitable for their intended use and meet applicable quality and regulatory expectations.
Savillex’s expanded portfolio is intended to provide pharmaceutical and biopharmaceutical customers with additional options as they evaluate and implement fluid management solutions.
The inclusion of Aramus™ and PE bags, together with single-use assemblies and associated components, increases the range of products available through the company. Combined with Savillex’s existing containment and bioprocessing offerings, the portfolio is expected to support a wider variety of customer requirements.
As drug developers continue to advance complex therapies and refine manufacturing operations, access to suitable fluid management technologies remains an important consideration. Savillex’s acquisition positions the company to address a broader set of these needs through its expanded product range and technical expertise.
Leadership Highlights Strategic Fit
Eric Giesing, Chief Executive Officer of Savillex, said the acquired Life Sciences Fluid Management business has established a strong reputation in high-purity single-use bioprocessing and that its product portfolio complements the company’s existing offerings.
“The Life Sciences Fluid Management business has built a strong reputation in high-purity single-use bioprocessing, and the Aramus product line is a natural fit alongside our Savillex, Containment and Bioprocessing offerings,” Giesing said.
He explained that the acquisition expands the company’s product portfolio and enables Savillex to provide a broader range of solutions to pharmaceutical and biopharmaceutical customers.
Giesing also highlighted the importance of welcoming the experienced team associated with the acquired business. The combination of established products and technical expertise is expected to support Savillex’s ongoing investments in technologies intended to help customers develop and manufacture critical therapies.
His comments reflect the company’s focus on building a more comprehensive offering by combining existing capabilities with products and expertise acquired through the transaction.
For Savillex, the integration of the new business represents an opportunity to strengthen its relationships with customers that require high-purity fluid handling solutions across multiple manufacturing stages.
Broader Capabilities to Support Global Pharmaceutical Customers
Chris Bedi, General Manager of Fluid Management at Savillex, said the acquisition creates an opportunity to bring a wider portfolio of fluid management solutions to pharmaceutical and biopharmaceutical customers worldwide.
“This acquisition creates an exciting opportunity to bring a broader portfolio of high-value fluid management solutions to pharmaceutical and biopharmaceutical customers worldwide,” Bedi said.
He noted that the acquired portfolio complements Savillex’s existing capabilities and will support the company’s continued efforts to provide innovative solutions throughout the drug development process.
Bedi also emphasized the opportunity to strengthen support for customers working to bring new medicines to patients around the world.
The comments underscore the role of product breadth and technical expertise in serving a pharmaceutical manufacturing sector that includes organizations at different stages of development and commercial maturity.
Early-stage biotechnology companies may require fluid management products for laboratory research and process development, while larger pharmaceutical manufacturers may need solutions that can be incorporated into established clinical or commercial manufacturing workflows.
A broader portfolio can help a supplier address these varied requirements, although individual customer needs will continue to depend on the products being manufactured, the design of the process, and applicable technical and quality specifications.
Through the acquisition, Savillex intends to expand its ability to support customers across this spectrum of activities.
Continued Investment in Innovation, Quality, and Customer Partnerships
Savillex said the acquisition advances its strategy of delivering industry-leading solutions for the life sciences market. The company remains focused on investing in innovation, quality, and customer partnerships while expanding its portfolio to meet the changing needs of pharmaceutical and biopharmaceutical manufacturers.
The addition of the Life Sciences Fluid Management business broadens the range of products available through Savillex and brings an experienced team into the organization. Integrating these resources will be an important part of realizing the strategic objectives associated with the transaction.
The acquisition also reinforces the importance of fluid management technologies within the wider pharmaceutical manufacturing ecosystem. While the development of a medicine depends on scientific research and clinical evidence, bringing therapies to patients also requires manufacturing processes and supporting technologies capable of meeting demanding operational and quality requirements.
Fluid handling products and single-use components form part of this supporting infrastructure. Their role varies by application, but they can be important elements in the processes used to develop and manufacture pharmaceutical and biological products.
For suppliers, expanding technical capabilities and product offerings can create opportunities to serve customers more comprehensively. For manufacturers, a broader selection of solutions may provide additional options when designing, evaluating, and optimizing production workflows.
Savillex’s acquisition brings together its existing high-purity fluid handling solutions with the acquired business’s single-use bioprocessing products and expertise. The company expects this combination to strengthen its ability to support customers from discovery and clinical development through commercial manufacturing.
Transaction Details
Savillex confirmed that it has completed the acquisition of Entegris, Inc.’s Life Sciences Fluid Management business. The transaction includes the acquired portfolio of bioprocessing and pharmaceutical manufacturing solutions, including Aramus™ and PE bags, single-use assemblies, and associated fluid management components.
EC M&A served as financial advisor to Savillex, while Sidley Austin LLP acted as legal counsel. The financial terms of the transaction were not disclosed.
With the acquisition completed, Savillex is expanding its life sciences portfolio and adding established technologies and experienced personnel to its fluid management business. The company’s next steps will center on bringing these complementary capabilities together and continuing to develop solutions for pharmaceutical and biopharmaceutical customers worldwide.
The transaction marks a further expansion of Savillex’s role in the life sciences supply chain, with an emphasis on high-purity fluid management, single-use technologies, and support for manufacturing activities across the drug development lifecycle.
About Savillex
Savillex is a leader in providing high-purity fluid handling solutions for life science and laboratory applications worldwide. Since its founding in 1976, Savillex’s goal has remained the same: to provide the world’s best container and containment solutions to users worldwide, whatever the application. Savillex is headquartered in Eden Prairie, Minnesota, USA, with manufacturing facilities in Minnesota and California, USA; Middlewich, UK; and Spain. For more information about Savillex, visit www.savillex.com.